Lycopene Mitigates Cisplatin-Triggered Renal Injury in Sprague-Dawley Rat Model

Abstract

Background: Cisplatin is a commonly used chemotherapy drug that works well for various solid cancers. Nevertheless, its therapeutic effectiveness is restricted by the risk of nephrotoxicity,which can significantly impact long-term patient outcomes. Problem: The problem addressed in this study is the nephrotoxicity associated with cisplatin treatment which can lead to kidney damage compromised renal performance. Method: This study explored lycopene's (LP) potential to mitigate cisplatin-triggered renal injury in a Sprague Dawley rat model. The study consisted of five groups(n=5): a control group receiving normal saline, a group administered with cisplatin (10 mg/kg) , a group administered with lycopene (100 mg/kg), a group administered with cisplatin followed by lycopene, and a group administered with lycopene followed by cisplatin. The treatment lasted for 28 days. Contribution: The study found that lycopene co-treatment mitigated cisplatin-triggered kidney damage,oxidative stress, and inflammation. Lycopene restored kidney antioxidant enzyme activities and diminished renal inflammation markers.Histopathological examination revealed that lycopene treatment reversed cisplatin-triggered kidney damage and promotedrenal tissue regeneration. These observations imply that lycopene may be a promising option for adjunctive therapy to reduce cisplatin-triggered nephrotoxicity.